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Summary. It has become clear that disruptions in the 
genome of somatic cells play a causative role in tumour 
development. We know that the ultimate formation of a 
malignancy is the result of a multistep process in which 
the functional loss andlor the altered or increased 
expression of genes play important roles. One such 
family of genes are the oncogenes, encoding protein 
products with mainly growth stimulating effects. 
Platelet-derived growth factor (PDGF) belongs to the 
family of oncogenes. It is likely that PDGF plays an 
essential role in the development of at least a subgroup 
of malignant astrocytic tumours that do not contain 
amplification of the EGF-receptor. The expression of 
PDGF a-receptors is related to tumour progression in 
these tumours, and some of the most malignant tumours 
were shown to contain amplification of the PDGF a- 
receptor. It is also clear now from several experimental 
studies that PDGF can drive the transformed phenotype, 
and that PDGF antagonists, by blocking the PDGF 
autocrine pathway revert the transformed phenotype of 
certain tumour cells. Because of the findings that 
receptor protein tyrosine kinases such as the EGF- and 
the PDGF-receptor play a crucial role in the develop- 
ment of gliomas, it is possible that inhibitors of the 
phosphorylation of the protein tyrosine kinases will be 
future candidates for glioma therapy. They might be able 
to at least delay the development of a fully malignant 
glioma. The role of PDGF in other tumours of neuroglial 
origin in the central nervous system has not been studied 
as extensively as its role in gliomas. Recent data suggest 
that also for the primitive neuroectodermal tumours 
overexpression of the PDGF a-receptor is related to 
malignancy of the tumours. For other tumours, such as 
neuroblastomas, PDGF exerts a differentiating rather 
than a mitogenic function and is an important survival 
factor. Further studies are needed to elucidate the role of 
PDGF in these non-glial primary brain tumours. 
Moreover, for a complete understanding of the role of 
PDGF in malignancies of the CNS, it is important to 
explore its function in the development of the normal 
Offprint requests to: Dr. Anja Smits, Department of Neurology, 
University Hospital Uppsala, S-751 85 Uppsala, Sweden 
CNS further. 
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Introduction 
Despite recent advances in clinical oncology during 
the last decades, the possibility of a curative treatment of 
malignant brain tumours still seems remote. Most 
patients recieve intracranial operation as a first choice 
treatment. However, a number of complicating factors, 
such as tumour localization in the vicinity of vital nerve 
and blood vessel structures as  well as  the often 
extremely malignant behaviour of the tumour with 
infiltrative growth and micrometastases within the brain, 
may make radical resection impossible (Russel and 
Rubinstein, 1989). It is therefore highly warranted to 
look for alternative treatments. Understanding the 
biological behaviour of the tumour is a prerequisite for a 
rational non-surgical treatment. 
During the last decade, huge advances have been 
made in the understanding of the genetics of cancer. 
Developments in molecular biology have pointed out the 
involvement of several families of genes in the 
development of human cancer. One such gene family is 
the family of oncogenes, including the family of growth 
factors and growth factor receptors. Oncogenes are 
altered versions of normal cellular genes (proto- 
oncogenes) that are involved in the regulation of 
normal cell growth, development and cell death. By 
several genetic alterations the proto-oncogene can be 
converted into an oncogene with transforming activity 
(Westermark et al., 1990). 
One of the classic examples of the close relationship 
between the protein products of proto-oncogenes and the 
products of oncogenes was the discovery in 1983 that 
the Platelet-derived Growth Factor (PDGF) B-chain is 
the cellular counterpart of the transforming protein of 
simian sarcoma virus (SSV), p28sis (Doolittle et al., 
1983; Waterfield et al., 1983). It was then shown that 
SSV-transformed cells secreted a molecule with PDGF- 









